Transatlantic partnership MedPharm recently formed a trans-atlantic collaboration with Purna Pharmaceuticals NV to serve global clients, signaling interest in expanding geographic reach and joint development capabilities that could open channel opportunities in Europe and beyond.

Expansion momentum A new 97,000 sq ft manufacturing facility in Durham, NC, alongside existing UK and US sites, indicates capacity growth and potential for larger contract manufacturing engagements, accelerated project timelines, and onshore supply security for North American customers.

Topical and transdermal focus MedPharm’s specialization in topical and transdermal drug development and manufacturing suggests opportunities to engage with brands seeking non-oral delivery systems, including formulation, clinical supply, and commercial-scale production for skin-applicable therapies.

Innovation and recognition Recognition as a finalist in multiple CPHI Pharma Award categories and specific approval of MedSpray Aerosol Technology and MedCast models highlight a technology-driven value proposition that can appeal to partners needing differentiated deliverables and innovative device/formulation approaches.

Leadership and capability build Recent leadership appointment in the U.S. analytical team and a broadened analytical suite indicate strengthened regulatory, analytical, and quality competencies, enabling more complex projects and faster regulatory-ready data packages for clients planning global trials.